{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:07:28Z","timestamp":1792382848051,"version":"4.4.0"},"reference-count":21,"publisher":"Federa\u00e7\u00e3o das Associa\u00e7\u00f5es de Ginecologia e Obstetr\u00edcia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,15]]},"DOI":"10.61622\/rbgo\/2025rbgo46","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:53:54Z","timestamp":1752681234000},"source":"Crossref","is-referenced-by-count":9,"title":["Vaginal estrogen therapy for treatment of menopausal genitourinary syndrome among breast cancer survivors: a systematic review and meta-analysis"],"prefix":"10.61622","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7685-6879","authenticated-orcid":false,"given":"Gabriel Moreira Lima","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7806-3034","authenticated-orcid":false,"given":"Augusto Ostermann","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0617-0927","authenticated-orcid":false,"given":"Pedro do Valle","family":"Teichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9085-4605","authenticated-orcid":false,"given":"Maria Celeste Os\u00f3rio","family":"Wender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"47794","reference":[{"issue":"11","key":"key20250716155348_B1","doi-asserted-by":"crossref","first-page":"dju289","DOI":"10.1093\/jnci\/dju289","article-title":"Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality","volume":"106","author":"Mu\u00f1oz","year":"2014","unstructured":"Mu\u00f1oz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014;106(11):dju289. doi: 10.1093\/jnci\/dju289","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"key20250716155348_B2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/GME.0000000000001121","article-title":"Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer","volume":"25","author":"Faubion","year":"2018","unstructured":"Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer. Menopause. 2018;25(6):596-608. doi: 10.1097\/gme.0000000000001121","journal-title":"Menopause"},{"issue":"10","key":"key20250716155348_B3","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society","volume":"21","author":"Portman","year":"2014","unstructured":"Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-8. doi: 10.1097\/GME.0000000000000329","journal-title":"Menopause"},{"issue":"6","key":"key20250716155348_B4","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/j.clbc.2019.07.007","article-title":"The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis","volume":"19","author":"Pavlovi\u0107","year":"2019","unstructured":"Pavlovi\u0107 RT, Jankovi\u0107 SM, Milovanovi\u0107 JR, Stefanovi\u0107 SM, Foli\u0107 MM, Milovanovi\u0107 OZ, et al. The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis. Clin Breast Cancer. 2019;19(6):e731-e740. doi: 10.1016\/j.clbc.2019.07.007","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"key20250716155348_B5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/AOG.0000000000004601","article-title":"Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus","volume":"138","year":"2021","unstructured":"Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus. Obstet Gynecol. 2021;138(6):950-60. doi: 10.1097\/AOG.0000000000004601","journal-title":"Obstet Gynecol"},{"issue":"8","key":"key20250716155348_B6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.clbc.2017.05.008","article-title":"Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists","volume":"17","author":"Biglia","year":"2017","unstructured":"Biglia N, Bounous VE, D\u2019Alonzo M, Ottino L, Tuninetti V, Robba E, et al. Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists. Clin Breast Cancer. 2017;17(8):611-7. doi: 10.1016\/j.clbc.2017.05.008","journal-title":"Clin Breast Cancer"},{"issue":"8","key":"key20250716155348_B7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.clbc.2023.08.003","article-title":"Safety and serum estradiol levels in hormonal treatments for vulvovaginal atrophy in breast cancer survivors: a systematic review and meta-analysis","volume":"23","author":"Comini","year":"2023","unstructured":"Comini AC, Carvalho BM, Moreira MJ, Reis PC, Colapietro L, Northern J, et al. Safety and serum estradiol levels in hormonal treatments for vulvovaginal atrophy in breast cancer survivors: a systematic review and meta-analysis. Clin Breast Cancer. 2023;23(8):835-46. doi: 10.1016\/j.clbc.2023.08.003","journal-title":"Clin Breast Cancer"},{"issue":"10","key":"key20250716155348_B8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnci\/93.10.754","article-title":"Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality","volume":"93","author":"O\u2019Meara","year":"2001","unstructured":"O\u2019Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst. 2001;93(10):754-62. doi: 10.1093\/jnci\/93.10.754","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"key20250716155348_B9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5694\/j.1326-5377.2002.tb04835.x","article-title":"Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality","volume":"177","author":"Durna","year":"2002","unstructured":"Durna EM, Wren BG, Heller GZ, Leader LR, Sjoblom P, Eden JA. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust. 2002;177(7):347-51. doi: 10.5694\/j.1326-5377.2002.tb04835.x","journal-title":"Med J Aust"},{"issue":"1","key":"key20250716155348_B10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/cmt.6.1.45.52","article-title":"A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer","volume":"6","author":"Dew","year":"2003","unstructured":"Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric. 2003;6(1):45-52.","journal-title":"Climacteric"},{"issue":"2","key":"key20250716155348_B11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","article-title":"Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study","volume":"135","author":"Le Ray","year":"2012","unstructured":"Le Ray I, Dell\u2019Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012;135(2):603-9. doi: 10.1007\/s10549-012-2198-y","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"key20250716155348_B12","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djac112","article-title":"Systemic or vaginal hormone therapy after early breast cancer: a Danish Observational Cohort Study","volume":"114","author":"Cold","year":"2022","unstructured":"Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or vaginal hormone therapy after early breast cancer: a Danish Observational Cohort Study. J Natl Cancer Inst. 2022;114(10):1347-54. doi: 10.1093\/jnci\/djac112","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"key20250716155348_B13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/AOG.0000000000005294","article-title":"Safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast cancer","volume":"142","author":"Agrawal","year":"2023","unstructured":"Agrawal P, Singh SM, Able C, Dumas K, Kohn J, Kohn TP, et al. Safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast cancer. Obstet Gynecol. 2023;142(3):660-8. doi: 10.1097\/AOG.0000000000005294","journal-title":"Obstet Gynecol"},{"issue":"1","key":"key20250716155348_B14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/jamaoncol.2023.4508","article-title":"Vaginal estrogen therapy use and survival in females with breast cancer","volume":"10","author":"McVicker","year":"2024","unstructured":"McVicker L, Labeit AM, Coupland CA, Hicks B, Hughes C, McMenamin U, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2024;10(1):103-8. doi: 10.1001\/jamaoncol.2023.4508","journal-title":"JAMA Oncol"},{"issue":"6","key":"key20250716155348_B15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/09513591003632258","article-title":"Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study","volume":"26","author":"Biglia","year":"2010","unstructured":"Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010;26(6):404-12. doi: 10.3109\/09513591003632258","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"key20250716155348_B16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors","volume":"17","author":"Kendall","year":"2006","unstructured":"Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17(4):584-7. doi: 10.1093\/annonc\/mdj127","journal-title":"Ann Oncol"},{"issue":"2","key":"key20250716155348_B17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-014-2930-x","article-title":"Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(\u00ae)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study","volume":"145","author":"Donders","year":"2014","unstructured":"Donders G, Neven P, Moegele M, Lintermans A, Bellen G, Prasauskas V, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(\u00ae)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat. 2014;145(2):371-9. doi: 10.1007\/s10549-014-2930-x","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"key20250716155348_B18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial","volume":"3","author":"Melisko","year":"2017","unstructured":"Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2017;3(3):313-9. doi: 10.1001\/jamaoncol.2016.3904","journal-title":"JAMA Oncol"},{"issue":"1","key":"key20250716155348_B19","first-page":"187","article-title":"Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors","volume":"29","author":"Streff","year":"2021","unstructured":"Streff A, Chu-Pilli M, Stopeck A, Chalasani P. Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors. Support Care Cancer. 2021;29(1):187-91. doi: 10.1007\/s00520-020-05466-1","journal-title":"Support Care Cancer"},{"issue":"5","key":"key20250716155348_B20","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/GME.0000000000001497","article-title":"Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial","volume":"27","author":"Hirschberg","year":"2020","unstructured":"Hirschberg AL, S\u00e1nchez-Rovira P, Presa-Lorite J, Campos-Delgado M, Gil-Gil M, Lidbrink E, et al. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause. 2020;27(5):526-34. doi: 10.1097\/GME.0000000000001497","journal-title":"Menopause"},{"issue":"1","key":"key20250716155348_B21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/GME.0000000000000956","article-title":"Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study","volume":"25","author":"Crandall","year":"2018","unstructured":"Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. 2018;25(1):11-20. doi: 10.1097\/GME.0000000000000956","journal-title":"Menopause"}],"container-title":["Revista Brasileira de Ginecologia e Obstetr\u00edcia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:53:57Z","timestamp":1752681237000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalrbgo.org\/article\/vaginal-estrogen-therapy-for-treatment-of-menopausal-genitourinary-syndrome-among-breast-cancer-survivors-a-systematic-review-and-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":21,"alternative-id":["10.61622\/rbgo\/2025rbgo46"],"URL":"https:\/\/doi.org\/10.61622\/rbgo\/2025rbgo46","relation":{},"ISSN":["0100-7203","1806-9339"],"issn-type":[{"value":"0100-7203","type":"print"},{"value":"1806-9339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e-rbgo46"}}